Home » Stocks » ADRO

Aduro BioTech, Inc. (ADRO)

Oct 6, 2020 - ADRO merged into KDNY
Stock Price: $14.60 USD 0.00 (0.00%)
Updated Oct 5, 2020 4:00 PM EDT
Market Cap 236.61M
Revenue (ttm) 27.96M
Net Income (ttm) -64.56M
Shares Out 16.17M
EPS (ttm) -4.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day Oct 5, 2020
Last Price $14.60
Previous Close $14.60
Change ($) 0.00
Change (%) 0.00%
Day's Open -
Day's Range 13.92 - 14.86
Day's Volume 0
52-Week Range 4.51 - 20.20

News

Hide News
Zacks Investment Research - 4 months ago

Does Aduro Biotech (KDNY) have what it takes to be a top stock pick for momentum investors? Let's find out.

GlobeNewsWire - 4 months ago

Combined Company Will H ave Over $275 Million in Operating Capital and Trade on Nasdaq under the Ticker Symbol “KDNY”

GlobeNewsWire - 4 months ago

One-for-Five Reverse Stock Split to be Effective October 2, 2020

GeekWire - 6 months ago

Chinook Therapeutics, a biotech company creating targeted therapies for kidney diseases, raised an additional $106 million just before its planned merger with Aduro Biotech.

Zacks Investment Research - 6 months ago

Aduro Biotech (ADRO) delivered earnings and revenue surprises of -10.53% and 76.06%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 6 months ago

BERKELEY, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the A Proliferati...

Zacks Investment Research - 6 months ago

Aduro Biotech (ADRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 8 months ago

BERKELEY, Calif., June 24, 2020 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of...

GeekWire - 8 months ago

Chinook Therapeutics, a biotech company creating targeted therapies for kidney diseases, has agreed to merge with Berkeley, Calif.

GlobeNewsWire - 8 months ago

BERKELEY, Calif., June 02, 2020 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of...

GlobeNewsWire - 8 months ago

– Combined Company Will Operate as Chinook Therapeutics and Advance Pipeline of Clinical-Stage Programs in Kidney Diseases, Led by Atrasentan and BION-1301 in IgA Nephropathy

Zacks Investment Research - 9 months ago

As of late, it has definitely been a great time to be an investor in Aduro Biotech.

Zacks Investment Research - 9 months ago

Aduro Biotech (ADRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research - 9 months ago

Is (ADRO) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 9 months ago

Aduro Biotech (ADRO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Investment Research - 9 months ago

Aduro Biotech (ADRO) delivered earnings and revenue surprises of 18.18% and 58.34%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 9 months ago

Aduro Biotech (ADRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 10 months ago

Aduro Biotech (ADRO) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 10 months ago

Aduro Biotech (ADRO) closed the most recent trading day at $2.54, moving +1.2% from the previous trading session.

Zacks Investment Research - 10 months ago

Is (ADRO) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 11 months ago

Aduro (ADRO) incurs wider-than-expected loss in Q4. Revenues too fall short of the mark.

Zacks Investment Research - 11 months ago

Aduro Biotech (ADRO) delivered earnings and revenue surprises of -14.29% and -26.61%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the st...

Zacks Investment Research - 11 months ago

Aduro Biotech (ADRO) closed the most recent trading day at $3.33, moving -0.6% from the previous trading session.

Zacks Investment Research - 11 months ago

After a painful stretch, small-cap U.S. stocks should rebound on a few tailwinds.

Other stocks mentioned: RAD, SMED, TNAV, VXRT
Zacks Investment Research - 11 months ago

Is (ADRO) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 1 year ago

Aduro Biotech (ADRO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 1 year ago

Aduro Biotech (ADRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

GlobeNewsWire - 1 year ago

BERKELEY, Calif., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of...

GlobeNewsWire - 1 year ago

BERKELEY, Calif., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the immune system...

Zacks Investment Research - 1 year ago

Aduro Biotech (ADRO) reported earnings 30 days ago. What's next for the stock?

GlobeNewsWire - 1 year ago

BERKELEY, Calif., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of...

Zacks Investment Research - 1 year ago

Aduro's (ADRO) loss misses estimates in Q3 while revenues almost match the mark.

Zacks Investment Research - 1 year ago

Aduro Biotech (ADRO) delivered earnings and revenue surprises of -13.04% and 5.47%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 1 year ago

BERKELEY, Calif., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of...

GlobeNewsWire - 1 year ago

BERKELEY, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that Andrea van Elsas, chief scientific officer of Aduro, is scheduled to present at t...

GlobeNewsWire - 1 year ago

BERKELEY, Calif., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator o...

GlobeNewsWire - 1 year ago

BERKELEY, Calif., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, is s...

Zacks Investment Research - 1 year ago

Aduro Biotech (ADRO) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 1 year ago

Aduro (ADRO) suffers wider-than-expected loss in the second quarter while revenues match estimates.

Zacks Investment Research - 1 year ago

Aduro (ADRO) presents updated data from an ongoing phase Ib study evaluating its STING agonist, ADU-S100 in combination with Novartis' checkpoint inhibitor.

Zacks Investment Research - 1 year ago

Aduro (ADRO) suspends the BION-1301 program for MM in Q1 due to severe competition.

Zacks Investment Research - 1 year ago

Aduro Biotech (ADRO) delivered earnings and revenue surprises of -70.59% and -51.23%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Aduro Biotech (ADRO) reported earnings 30 days ago. What's next for the stock?

About ADRO

Aduro Biotech, an immunotherapy company, focuses on the discovery, development, and commercialization of therapies to harness the body's natural immune system for the treatment of patients with challenging diseases. The company is developing ADU-S100, which is in Phase I dose escalation clinical trial and Phase Ib dose escalation clinical trial in combination with spartalizumab to treat patients with advanced, metastatic treatment-refractory solid tumors; Phase I clinical trial in combination with ipilimumab for the treatment of relapsed and re... [Read more...]

Industry
Biotechnology
IPO Date
Apr 15, 2015
CEO
Stephen T. Isaacs
Employees
69
Stock Exchange
NASDAQ
Ticker Symbol
ADRO
Full Company Profile

Financial Performance

In 2019, Aduro BioTech's revenue was $17.26 million, an increase of 14.39% compared to the previous year's $15.09 million. Losses were -$82.37 million, -13.62% less than in 2018.

Financial Statements